Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraphene Nanochem Regulatory News (GRPH)

  • There is currently no data for GRPH

Interim Results

29 Sep 2008 10:49

RNS Number : 5376E
Biofutures International plc
29 September 2008
Β 

ο»Ώ

For Immediate Release 29 September 2008

Biofutures International plc

Interim ResultsΒ for the six months ended 30 June 2008

Biofutures International plc, the AIM listedΒ investing company whichΒ seeks to establish, invest in, or acquire assets, partnerships, joint ventures, businesses or companies in Europe, Asia and the Middle East in the energy and utility sectors and their related infrastructures today announces its results for the six months ended 30 June 2008.Β 

CHAIRMAN'S STATEMENT

I am pleased to present our interim resultsΒ for theΒ sixΒ monthsΒ endedΒ 30 JuneΒ 2008.

The loss for the 6 month period ended 30 June 2008 was Β£(145,000) compared to Β£(449,000) for the same period in 2007. The Directors have focussed on the conservation of shareholder value through a reduction in administrative expenses to Β£356,000 for the 6 month period ended 30 June 2008Β fromΒ Β£682,000 for the same period in 2007,Β while actively pursuing the Group's investing strategy. Cash at 30 June 2008 was Β£8,095,000 compared to Β£8,650,000 at 30 June 2007.

On 16Β May 2008, we announced that we had terminated our contract to purchase the 50 acres of land at Lahad Datu, Sabah, Malaysia and agreed, in its place, to purchase 14 acres of land at the same locationΒ ("Lahad Datu land"). This agreement leaves us with sufficient acreage to build a palm oil refinery plant (and to add the additional modules to convert it to a 200,000 metric tonnes biodiesel plant should it become economicallyΒ viable to do so in the future) and has allowed us to save approximately Β£2.90 million which would otherwise have been spent on acquiring the 50 acre plot of land.

We also subsequently announced the findings of our review of our Zurex project and concluded that the biodiesel plant as originally conceived was currently not economically viable. The management has been actively pursuing alternative options for the Company. We have continued our discussions with Lurgi and are carrying out due diligence on the feasibility of re-engineering the project so that a palm oil refinery plant can be built, utilising the Lahad Datu land and some of the equipment already constructed or procured from Lurgi. This refinery, through the addition of a trans-esterification module or an esterification module and associated ancillary equipment, could be expanded to produce palm oil biodiesel should it become economically viable to do so. We have applied for the necessary licence to produce refined palm oil and are awaiting a decision from the appropriate department inΒ Malaysia. In the meantime we are finalising our due diligence on thisΒ refinery project.

Board Changes

We welcomed to the Board David Long as a Non Executive Director with effect from 5 February 2008. David has many years' experience in business operational management and business accounting processes within the paint and chemical industry.

Group Strategy

At the Extraordinary General Meeting (EGM)Β 6Β June 2008, the Company became an Investing Company. The Group's strategy is to continue to review the biodiesel plant project to be carried out by Zurex including potentially re-engineering it into a palm oil refinery. In addition, the Group's strategy is to invest in or acquire projects, assets, partnerships, joint ventures, businesses or companies (public or private) in Europe, Asia and theΒ Middle EastΒ in the energy and utility sectors and their related infrastructures.

As an Investing Company,Β Biofutures will therefore have to make an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules for Companies or otherwise implement its Investing Strategy to the satisfaction of the London Stock ExchangeΒ by 6 June 2009. If this does not occur, trading in the Company's ordinary shares will be suspended. Such an investment could be an investment in the palm oil refinery project.

Outlook

The broader investment strategy adopted at the June EGM provides the Company with the flexibility to utilise its current cash resources for the benefit of shareholders. The palm oil refinery project is being actively pursued as a potential project. The Company is also seeking other investments which should add to shareholder value.

David Yeoh

Executive Chairman

29Β SeptemberΒ 2008

Enquiries:

Julie Pomeroy, Group Finance Director,

Biofutures International plc

Tel: 0117 920 0092

Emily Morgan,Β 

Blomfield Corporate Finance

Tel: 01275 871717

Paul Vann

Winningtons Financial

Tel: 0117 920 0092

Β Β 

UNAUDITEDΒ CONSOLIDATEDΒ INCOMEΒ STATEMENT

FOR THEΒ SIX MONTHSΒ TOΒ 30 JUNE 2008

Notes

Six months to 30 June 2008

Six months to 30 June 2007

Year ended 31 December 2007

Β£'000s

Β£'000s

Β£'000s

ContinuingΒ operations

Revenue

-

-

-

Administrative expenses

(356)

(682)

(891)

Impairment

-

Β 

-

(2,400)

Operating loss

(356)

(682)

(3,291)

Interest expense

-

-

(76)

InterestΒ income

211

233

484

Loss before income tax

(145)

(449)

(2,883)

Income tax expense

3

-

-

-

Loss for the period

(145)

(449)

(2,883)

Loss per share

- BasicΒ and diluted

4

(0.10)Β p

(0.30)p

(1.94)p

UNAUDITEDΒ CONSOLIDATEDΒ STATEMENT OF CHANGESΒ IN EQUITY

Six months to 30 June 2008Β 

Six months to 30 June 2007Β 

Year ended 31 December 2007

Β 

Β£'000s

Β£'000s

Β£'000s

Loss for the period

(145)

(449)

(2,883)

Net exchange adjustments

22

(40)

39

Total recognised income and expenses for the period

(123)

(489)

(2844)

Share-based compensation

4

196

(56)

Shares issued

-

-

33

Transactions with equity holders

4

196

(23)

TotalΒ movement in equity

(119)

(293)

(2,867)

Opening shareholders'Β funds

26,568

29,435

29,435

Closing shareholders' funds

26,449

29,142

26,568

Β Β 

UNAUDITEDΒ CONSOLIDATEDΒ BALANCE SHEETΒ 

As atΒ 30 June 2008

As atΒ 30 June 2007

As at 31 Dec 2007

Assets

Β£'000s

Β£'000s

Β£'000s

Non-current assets

Property, plant and equipment

1,971

3,771

1,938

Goodwill

6,078

6,078

6,078

IntangibleΒ assets

10,850

10,850

10,850

18,899

20,699

18,866

Current assets

Trade and other receivablesΒ 

43

59

68

Cash and cash equivalents

8,095

8,650

8,329

8,138

8,709

8,397

Total assets

27,037

29,408

27,263

Equity and liabilities

Equity

Share capital

1,510

1,477

1,510

Share premium account

11,293

11,293

11,293

Merger reserve

16,001

16,001

16,001

Translation reserve

58

(42)

37

Share based scheme reserve

1,037

1,285

1,033

Retained earnings

(3,451)

(872)

(3,306)

Total equityΒ 

26,448

29,142

26,568

Current liabilities

Trade and other payablesΒ 

589

266

695

Total liabilities

589

266

695

Total equity and liabilities

27,037

29,408

27,263

Β Β 

UNAUDITEDΒ CASH FLOW STATEMENTΒ 

Notes

Six months toΒ 30 June 2008

Six months toΒ 30 June 2007

Year ended 31 December 2007

Β£000s

Β£000s

Β£000s

Cash flow from operating activities

CashΒ generatedΒ from operationsΒ 

5

(435)

(729)

(891)

Net cashΒ generatedΒ for operating activitiesΒ 

(435)

(729)

(891)

Cash flow fromΒ investingΒ activities

Costs relating to acquisition of subsidiary

-

-

(275)

Purchases of property, plant and equipment

(5)

(2,068)

(2,359)

Interest received

211

233

484

Net cash used in investing activities

206

(1,835)

(2,150)

Cash flow from financing activities

Proceeds from issue of share capital

-

2,441

2,474

Net cash inflow from financing activities

-

2,441

2,474

Effects of exchange rate changes

(5)

(40)

83

Net increase in cash and cash equivalents

(234)

(163)

(484)

Cash atΒ beginning of period

8,329

8,813

8,813

Cash and cash equivalents as at end of period

8,095

8,650

8,329

Β Β 

UNAUDITED NOTES TO THE INTERIM STATEMENTS FOR THEΒ SIX MONTHSΒ TOΒ 30 JUNEΒ 2008

1Β  BasisΒ of preparation

TheΒ financial information contained in these financial statements comprises the Group balance sheets asΒ atΒ 30 JuneΒ 2008,Β 30Β JuneΒ 2007Β and 31 DecemberΒ 2007,Β the Group statement of income,Β the Group statement of cashflows and the Group statement of changes in equity for the half year ended 30 JuneΒ 2008Β andΒ 30 JuneΒ 2007Β andΒ the year endedΒ 31 December 2007.

The financial information set out on pagesΒ 2,Β 3 and 4Β is unaudited and does notΒ constituteΒ statutory accounts within the meaning ofΒ sectionΒ 240 of the Companies Act 1985. The comparative numbers for theΒ year endedΒ 31 DecemberΒ 2007Β have been extracted from the audited accounts which have been filed at Companies House and which carried an unqualified audit report with no statement under s237(2) or (3) of the Companies Act 1985.Β 

These condensed consolidated interim financial statements (the interim financial statements) have been prepared in accordance with the accounting policiesΒ as set out in the Group's annual financial statements for the year ended 31 December 2007 on pagesΒ 17 to 21Β Β which are based on the recognition and measurement principles of IFRS in issue as adopted by the European Union (EU) and are effective atΒ 30 June 2008Β or are expected to be adopted and effective atΒ 31 December 2008Β our annual reporting date which will use IFRS accounting standards adopted by the EU.Β 

The Interim Report has been drawn up on the basisΒ that the refineryΒ plantΒ discussed above will be built.Β Β However if the refineryΒ plant is not built, a significant write-off isΒ likely to be required as the intangible assetsΒ may have limited value in the current marketΒ conditionsΒ andΒ aΒ further write-off of tangible assets may be required.

Β Β 

2 Segmental Information

Primary reporting format - business segment:

Six months to 30 June 2008

Six months to 30 June 2007

Β Year ended 31 December 2007

Β£'000s

Β£'000s

Β£'000s

Operating loss

Operational

(121)

(108)

(2,591)

Head Office

(235)

(574)

(700)

Operating loss

(356)

(682)

(3,291)

LossΒ before income tax

Operational

(121)

(108)

(2,667)

Head Office

(24)

(341)

(216)

Loss for period

(145)

(449)

(2,883)

Loss forΒ period

Operational

(121)

(108)

(2,667)

Head Office

(24)

(341)

(216)

Loss for period

(145)

(449)

(2,883)

3 Income tax expenses

There is no tax charge due to the losses arising in the period.

4 Loss per share

Six months to June 30 2008

Six months to June 30 2007

Year ended 31 December 2007

Loss attributable to equity shareholders of the CompanyΒ 

Β£(145,000)

Β£(449,000)

Β£(2,883,000)

Weighted average number of ordinary shares in issue

151,060,000

147,730,000

148,979,891

Basic earnings per share in penceΒ 

(0.10)p

(0.30)p

(1.94)p

The impact ofΒ options andΒ warrants on the loss per share is anti-dilutiveΒ and therefore no diluted earnings per share figure haveΒ been included.

Β Β 

5 Cash generated from operations

Six months to June 30 2008

Six months to June 30 2007

Year ended 31 December 2007

Β£'000s

Β£'000s

Β£'000s

LossΒ before taxΒ 

(356)

(682)

(3,291)

Adjustments for:

Depreciation

4

-

7

Impairment

-

-

2,400

Share based payments

4

196

(56)

Changes in working capital

Trade and other receivables

25

45

36

Trade and other payables

(112)

(288)

13

Cash (outflow)Β fromΒ operations

(435)

(729)

(891)

6 Dividend

The directors do not recommendΒ the payment of aΒ dividend.

7Β  Availability of interim report

The Company's Interim Report will be availableΒ in hard copyΒ for one month fromΒ the Company's registered officeΒ atΒ One, St Paul's Churchyard,Β LondonΒ EC4M 8SH. The Company's Interim Report will also be available in soft copy fromΒ the investors section ofΒ the Company's website;Β www.biofuturesplc.com, at least until the publication of the next annual reportΒ pursuant to Rule 26 of the AIM Rules for Companies.Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR IIFSAAVIAFIT
Date   Source Headline
16th Mar 20187:00 amRNSAcquisition Update and AIM Cancellation
16th Feb 20187:00 amRNSConfirmation of Resignation of Nomad and Broker
31st Jan 20181:47 pmRNSNotice of Resignation of Nomad and Broker
17th Jan 20189:24 amRNSResignation of Director
8th Jan 20182:50 pmRNSProposed Acquisition Update
30th Nov 20177:30 amRNSSuspension - Graphene Nanochem Plc
30th Nov 20177:00 amRNSProposed Acquisition and Suspension of Trading
12th Oct 20174:40 pmRNSSecond Price Monitoring Extn
12th Oct 20174:35 pmRNSPrice Monitoring Extension
11th Oct 20174:40 pmRNSSecond Price Monitoring Extn
11th Oct 20174:35 pmRNSPrice Monitoring Extension
29th Sep 201711:30 amRNSInterim Results
13th Sep 20179:31 amRNSHolding(s) in Company
13th Sep 20179:27 amRNSHolding(s) in Company
11th Sep 201712:07 pmRNSSecond Price Monitoring Extn
11th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 201711:45 amRNSConversion of Loan Notes and Issue of Equity
4th Sep 201710:15 amRNSConversion of loan note and issue of equity
2nd Aug 20171:20 pmRNSConversion of loan note and issue of equity
26th Jul 201711:30 amRNSResult of Annual General Meeting
4th Jul 20179:59 amRNSConversion of loan note and issue of equity
30th Jun 20177:03 amRNSPreliminary Results
27th Jun 20174:35 pmRNSPrice Monitoring Extension
23rd Jun 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSPolymer Division Paid Pilot
22nd May 201712:54 pmRNSPlatDrill Deployment In Myanmar
15th May 201712:35 pmRNSIssuance of Tranche 2 Loan Notes
12th Apr 20172:47 pmRNSConversion of loan note and issue of equity
3rd Apr 201711:47 amRNSConversion of Loan Note and Issue of Equity
31st Mar 20179:05 amRNSUpdate on Debt Rationalisation
8th Mar 201712:00 pmRNSConversion of loan note and issue of equity
3rd Mar 20177:00 amRNSCommercial deployment in Turkmenistan
20th Feb 20174:40 pmRNSSecond Price Monitoring Extn
20th Feb 20174:35 pmRNSPrice Monitoring Extension
3rd Feb 20177:00 amRNSConversion of loan note and issue of equity
29th Dec 20164:19 pmRNSFurther information on 2015 report and accounts
28th Dec 20167:00 amRNSContract Win
23rd Dec 201612:35 pmRNSPrice Monitoring Extension
23rd Dec 20168:45 amRNSRestoration - Graphene NanoChem PLC
23rd Dec 20168:15 amRNSIssuance of Loan Notes and Resumption of Trading
6th Dec 20162:44 pmRNSResult of AGM
14th Nov 20165:04 pmRNSInterim Results
14th Nov 20165:01 pmRNSProposed Share Capital Reorganisation
14th Nov 20165:00 pmRNSPreliminary Results
31st Oct 20164:35 pmRNSUpdate on pending 2015 Annual Results
30th Sep 20163:20 pmRNSUpdate on 2015 Annual Results & 2016 Interims
1st Sep 20161:21 pmRNSUpdate on pending 2015 Annual Results
29th Jul 20167:00 amRNSUpdate on pending 2015 Annual Results
29th Jun 20167:30 amRNSSuspension - Graphene Nanochem Plc
29th Jun 20167:30 amRNSStatement re. Suspension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.